In the last few years, the use of checkpoint inhibitors such as ipilimumab (anti-CTLA4), pembrolizumab (anti-PD1), and nivolumab (anti-PD1) has improved the treatment of certain tumors, like melanoma and non-small-cell lung carcinoma [26]. This evidence concerns the gene CTLA4 and melanoma.